Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.

"Competing interests B.C.C.: consulting or advisory role (Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Ono Pharmaceutical, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, Merck Sharp & Dohme, Medpacto, Blueprint Medicines, KANAPH Therapeutics, BridgeBio, Cyrus Therapeutics, Guardant Health and Oscotec); board of directors (Interpark Bio Convergence and J INTS BIO); research funding (Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono Pharmaceutical, Dizal Pharma, Merck Sharp & Dohme, AbbVie, Medpacto, GI Innovation, Eli Lilly, Blueprint Medicines and Interpark Bio Convergence); royalties (Champions Oncology); stock ownership (TheraCanVac, Gencurix, BridgeBio, KANAPH Therapeutics, Cyrus Therapeutics, Interpark Bio Convergence and J INTS BIO); founder (DAAN Biotherapeutics). D.-W.K.: travel, accommodations and expenses (Daiichi Sankyo and Amgen); research funding to institution (Alpha Biopharma, AstraZeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan, Boehringer Ingelheim, Amgen and Daiichi Sankyo). A.I.S.: consulting or advisory role (Incyte, Amgen, Novartis, AstraZeneca/MedImmune, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda and Janssen); consulting or advisory role for institution (Array BioPharma, AstraZeneca/MedImmune, Merck and Bristol Myers Squibb); stock ownership (Eli Lilly); honoraria (CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen, Novartis, Bristol Myers Squibb and Bayer); research funding (LAM Therapeutics); research funding to institution (Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, LAM Therapeutics, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol Myers Squibb, LOXO Oncology, Arch Therapeutics, Gritstone Oncology, Plexxikon, Amgen, Daiichi Sankyo, ADC Therapeutics, Janssen, Mirati Therapeutics, Rubius and Synthekine); leadership role for institution (NEXT Oncology Virginia). J.E.G.: consulting or advisory role (AstraZeneca and Atara Biotherapeutics); honoraria (Bristol Myers Squibb and Celgene); speakers’ bureau (Bristol Myers Squibb); research funding to institution (Janssen); travel, accommodations and expenses (Atara Biotherapeutics, Bristol Myers Squibb and Celgene). E.B.H.: consulting or advisory role (Janssen, Revolution Medicines, and Ellipses Pharmaceuticals); research funding to institution (Revolution Medicines). S.-W.K.: consulting or advisory role (AstraZeneca, Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb, Amgen and Boehringer Ingelheim); speakers’ bureau (Boehringer Ingelheim and Amgen); research funding (AstraZeneca). R.E.S.: consulting or advisory role (AstraZeneca, EMD Serono, Blueprint Medicines, Daiichi Sankyo, Eli Lilly, Janssen Oncology, Macrogenics, Sanofi Aventis, Regeneron and Mirati Therapeutics); travel, accommodations and expenses (AstraZeneca); honoraria (AstraZeneca and Amgen); research funding to institution (Bristol Myers Squibb and MedImmune); research funding (Merck and AstraZeneca). E.K.C.: no relationships to disclose. K.H.L.: no relationships to disclose. A.M.: consulting or advisory boards (Janssen, Merck, Takeda, GSK and Genmab); honoraria (Chugai, Novartis Oncology, Faron Pharmaceuticals, Bayer and Janssen); expenses (Amgen and LOXO Oncology). J.-S.L.: consulting or advisory role (AstraZeneca and Ono Pharmaceutical). J.-Y.H.: consulting or advisory role (MSD Oncology, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Novartis, Takeda and Pfizer); honoraria (Roche, AstraZeneca, Bristol Myers Squibb and Takeda); research funding (Roche, Pfizer, Ono Pharmaceutical and Takeda). M.N.: consulting or advisory role (AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Pfizer, Eli Lilly, Genentech and Janssen); speakers’ bureau (Takeda and Blueprint Medicines); travel support (AnHeart Therapeutics). J.K.S.: consulting or advisory role (AstraZeneca, Janssen Oncology, Navire, Pfizer, Regeneron, Medscape and Takeda). S.-H.I.O.: advisory role (Elevation Oncology); stock ownership (Turning Point Therapeutics and Elevation Oncology); honorarium (Pfizer); advisory fees (BeiGene, Roche/Genentech, AstraZeneca, Takeda/ARIAD, Pfizer, Caris Life Science, Janssen, Daiichi Sankyo and Eli Lilly). P.L., J.M.B., J.C.C., A.R., G.G., J.X., M.T. and R.E.K.: employment and stock ownership (Johnson & Johnson). K.P.: consulting or advisory role (AstraZeneca, Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb, Merck Sharp & Dohme, Blueprint Medicines, Amgen, Merck, LOXO Oncology, AbbVie, Daiichi Sankyo, Boehringer Ingelheim, Johnson & Johnson, Eisai and Puma Biotechnology); speakers’ bureau (Boehringer Ingelheim and AZD); and research funding (AstraZeneca and Merck Sharp & Dohme)."

"We thank the patients who participated in the study and their families and caregivers; the physicians and nurses who cared for patients and supported this trial; and the staff members at the study sites and those involved in data collection and analyses. This clinical study was funded by Janssen R&D. Medical writing support was funded by Janssen Global Services and provided by T. T. Cao (Janssen Global Services) and Lumanity Communications."